Skip to main content

Table 2 Anti-melanoma therapy prior and subsequent to participation in the MACVAC trial. Therapies: overall and by treatment arm

From: Randomized phase II trial of autologous dendritic cell vaccines versus autologous tumor cell vaccines in metastatic melanoma: 5-year follow up and additional analyses

 

All (n = 42)

TCV (n = 24)

DCV (N = 18)

P-value

Previous therapy

 Surgeries Only

7 (17%)

3 (12%)

4 (22%)

0.44

 Radiation Therapy (not brain)

17 (40%)

8 (33%)

9 (50%)

0.28

 Brain Radiation Therapy

10 (24%)

6 (25%)

4 (22%)

1.00

 Chemotherapy

23 (55%)

15 (62%)

8 (44%)

0.24

 Interleukin-2

14 (33%)

8 (33%)

6 (33%)

1.00

 IFN-α

20 (48%)

11 (46%)

9 (50%)

0.79

 GMCSF

13 (31%)

8 (33%)

5 (28%)

0.70

 Anti-VEGF

8 (19%)

4 (17%)

4 (22%)

0.71

 Vaccine

5 (12%)

4 (17%)

1 (6%)

0.37

 Anti-BRAF

0

0

0

–

 Anti-CTLA4

1 (2%)

1 (4%)

0

–

 Anti-PD1

0

0

0

–

Subsequent therapy

 Metastasectomy

11 (26%)

4 (17%)

7 (39%)

0.16

 Radiation Therapy (not brain)

9 (21%)

6 (25%)

3 (17%)

0.71

 Brain Radiation Therapy

11 (26%)

6 (25%)

5 (28%)

1.00

 Chemotherapy

19 (45%)

11 (46%)

8 (44%)

1.00

 Interleukin-2

7 (8%

5 (21%)

2 (11%)

0.68

 IFN-α

3 (7%)

2 (8%)

1 (6%)

1.00

 GM-CSF

7 (17%)

4 (17%)

3 (17%)

1.00

 Anti-VEGF

4 (10%)

2 (8%)

2 (11%)

1.00

 Vaccine

1 (2%)

0

1 (6%)

–

 Anti-BRAF

7 (17%)

3 (12%)

4 (22%)

0.44

 Anti-CTLA4

12 (29%)

7 (29%)

5 (28%)

1.00

 Anti-PD1

1 (2%)

0

1 (6%)

0.43

 None

9 (21%)

7 (29%)

2 (11%)

0.26

  1. MACVAC melanoma antigen cancer vaccine trial, TCV tumor cell vaccine, DCV dendritic cell vaccine, IFN-α interferon alpha, GM-CSF granulocyte macrophage colony stimulating factor, VEGF monoclonal antibody to vascular endothelial growth factor, BRAF enzyme endcoded by mutated BRAF gene, CTLA4 cytotoxic T Lymphocyte Antigen 4, PD1 programmed death molecule 1